DCVax-L: Phase III ongoing

Northwest Biotherapeutics said the U.K.'s National Institute for Health Research (NIHR) "adopted" the biotech's double-blind, international Phase III trial of DCVax-L in up to 300 patients with newly diagnosed GBM as a national priority trial in the U.K. According to the company, priority trials are monitored by NIHR and receive financial and operational support, including funding for additional staff, as well as imposes penalties for shortfalls, including lags in enrollment. ...